Premium
Therapeutic Potential of Intramyocardial Transplanted CD34+ Cells in Myocardial Ischemia
Author(s) -
McKee Jeff,
Palmer Lora,
Rice Debbie,
Anderson Laura,
Gass Jerome,
Motlagh Delara,
Pokropinski Sharon,
Rausa Francisco,
McCallister Brian,
Jasani Bhumi,
Kemshead John,
Amrani David
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.1123.23
Subject(s) - cd34 , in vivo , peripheral blood mononuclear cell , clonogenic assay , transplantation , in vitro , medicine , cell , cardiology , pathology , stem cell , chemistry , biology , microbiology and biotechnology , biochemistry
Baxter's Isolex 300i Magnetic Cell Selection System isolates patient's CD34+ cells from peripheral blood. The mononuclear cell fraction is incubated with anti‐CD34 antibodies and captured using sheep anti‐mouse (SAM) IgG coated beads. The therapeutic potential of intramyocardial transplanted, autologous, SAM‐isolated CD34+ cells is under clinical investigation. Due to the theoretical potential for prion transmission and limited supply of the source sheep, a rat anti‐mouse (RAM) IgG coated bead has been developed. In vitro, RAM and SAM were comparable in their ability to isolate CD34+ cells. CD34+ cells demonstrated comparable yield, purity, viability, apoptosis, and cell subsets. CD34+ cells exhibited comparable clonogenic potential and migratory capacity in a dose‐dependant manner to VEGF and SDF‐1. In vivo , intramyocardial transplantation of RAM‐isolated human CD34+ cells improved cardiac performance in an athymic rat, left anterior descending coronary artery occlusion model. Echocardiographic evaluation demonstrated improvements in left ventricular fractional shortening (p<0.001) and left anterior wall thickening (p<0.01), and decreased ventricular fibrosis, similar to that reported by Kawamoto et al (2003) in support of the IND for SAM. In conclusion, these data suggest equivalent preclinical efficacy of RAM and SAM‐isolated human CD34+ cells. Baxter provided all research support.